Evaluating the Occurrence of Participation Trends Among Weight Loss Clinical Trials Patients

NCT06155552 | Not Yet Recruiting

• 1 other identifier: 66708946
• Study Type: observational
• Target: 500
• Locations: 1 country
• Sites: 1

Brief Summary

Clinical studies, with a distinct focus on weight loss, play a crucial role in evaluating the safety and effectiveness of novel treatments. These trials serve as instrumental means to determine whether new medications surpass conventional therapies, providing substantial evidence for their broader adoption. The primary objective is to meticulously scrutinize trial completion rates and voluntary withdrawals within this specific patient group.

Conditions

Weight Loss

Keywords

weight loss

Outcome Measures

Primary Outcomes (2)

• Rate of patients who decide to enroll in a weight loss clinical study.

  3 months

• Number of weight loss study participants who remain in clinical study until completion.

  12 months

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

Weight loss clinical trials patients who are actively considering enrolling in a clinical trial for the said condition, but have not yet completed enrollment and randomization phases.

You may qualify if:

• Interested in losing weight and not enrolled in a formal weight loss program or taking medications or supplements that may cause weight change
• Participant must be willing and able to comply with scheduled visits, treatment schedule, laboratory tests, and other requirements of the study.
• Aged ≥ 18 years old and ability to provide written informed consent obtained prior to participation in the study and any related procedures being performed

You may not qualify if:

• Enrolled in another research study
• Inability to provide written informed consent
• Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial

Sponsors & Collaborators

• Power Life Sciences Inc.: lead

Study Sites (1)

Power Life Sciences

San Francisco, California, 94107, United States

Location

Related Publications (3)

• Sarma S, Palcu P. Weight loss between glucagon-like peptide-1 receptor agonists and bariatric surgery in adults with obesity: A systematic review and meta-analysis. Obesity (Silver Spring). 2022 Nov;30(11):2111-2121. doi: 10.1002/oby.23563.

  PMID: 36321278 BACKGROUND

• Palacios OM, Kramer M, Maki KC. Diet and prevention of type 2 diabetes mellitus: beyond weight loss and exercise. Expert Rev Endocrinol Metab. 2019 Jan;14(1):1-12. doi: 10.1080/17446651.2019.1554430. Epub 2018 Dec 6.

  PMID: 30521416 BACKGROUND

• Jin S, Lu Q, Sun Y, Xiao S, Zheng B, Pang D, Yang P. Nutrition impact symptoms and weight loss in head and neck cancer during radiotherapy: a longitudinal study. BMJ Support Palliat Care. 2021 Mar;11(1):17-24. doi: 10.1136/bmjspcare-2019-002077. Epub 2020 Feb 4.

  PMID: 32019753 BACKGROUND

MeSH Terms

Conditions

Weight Loss

Condition Hierarchy (Ancestors)

Body Weight Changes; Body Weight; Signs and Symptoms; Pathological Conditions, Signs and Symptoms

Study Officials

• Michael B Gill

  Power Life Sciences Inc.

  STUDY DIRECTOR

Central Study Contacts

Michael B Gill

CONTACT

4159004227; bask@withpower.com

Study Design

• Study Type: observational
• Observational Model: CASE CROSSOVER
• Time Perspective: PROSPECTIVE
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: November 24, 2023
• First Posted: December 4, 2023
• Study Start: December 1, 2024
• Primary Completion: December 1, 2025
• Study Completion (Estimated): December 1, 2026
• Last Updated: December 4, 2023

Record last verified: 2023-11

Locations

US (1)